EyePoint (EYPT) Research & Development (2010 - 2026)
EyePoint (EYPT) posted Research & Development of $72.1 million for Q1 2026, up 144.61% sequentially from -$161.7 million in Q4 2025, and up 206037.14% YoY from N/an in Q1 2025.
EyePoint (EYPT) Research & Development (2010 - 2026) Analysis & Trends
EyePoint has reported Research & Development for 17 years, with the latest figure at $72.1 million in Q1 2026.
- Quarterly Research & Development rose 206037.14% year-over-year to $72.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.7 million (down 92.89% YoY) and the FY2025 annual result came in at $90000.0, down 99.93% from the prior year.
- Research & Development grew to $72.1 million in Q1 2026 per EYPT's latest filing, from -$161.7 million in the prior quarter.
- Over five years, Research & Development peaked at $132.8 million in Q4 2024 and troughed at -$161.7 million in Q4 2025.
- A 5-year average of $16.5 million and a median of $15.7 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2026: Research & Development tumbled 692.09% in 2023, then surged 206037.14% in 2026.
- Over 5 years, Research & Development stood at $5.9 million in 2022, then sank by 692.09% to -$35.0 million in 2023, then surged by 479.32% to $132.8 million in 2024, then tumbled by 221.75% to -$161.7 million in 2025, then soared by 144.61% to $72.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $72.1 million, -$161.7 million, and $47.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 83.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.61 Mn |
| Mar 31, 2026 | 72.15 Mn |
| Dec 31, 2025 | -161.74 Mn |
| Sep 30, 2025 | 47.75 Mn |
| Jun 30, 2025 | 55.50 Mn |
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | 132.85 Mn |
| Sep 30, 2024 | 29.54 Mn |
| Jun 30, 2024 | 29.82 Mn |
| Mar 31, 2024 | 30.14 Mn |
| Dec 31, 2023 | -35.02 Mn |
| Sep 30, 2023 | 17.36 Mn |
| Jun 30, 2023 | 15.73 Mn |
| Mar 31, 2023 | 5.74 Mn |
| Dec 31, 2022 | 5.92 Mn |
| Sep 30, 2022 | 11.16 Mn |
| Jun 30, 2022 | 12.99 Mn |
| Mar 31, 2022 | 9.95 Mn |
| Dec 31, 2021 | 1.60 Mn |
| Sep 30, 2021 | 8.50 Mn |